ArQule, Inc.

Oral B-RAF kinase inhibitors discovered

Published in Oncology Business Week, November 14th, 2004

ArQule, Inc., (ARQL) announced the discovery of a proprietary series of potent (nanomolar range), orally active inhibitors of RAF kinases with antitumor activity in a xenograft human cancer model.

"I am extremely encouraged that we have been able to integrate ArQule's proprietary chemistry with the growing strength and stature of the ArQule Biomedical Institute," said Stephen A. Hill, president and CEO of ArQule.

"It is exciting to see the early impact of our newly appointed research leaders - Dennis France and Shi-Chung Ng, on our growing oncology portfolio," Hill said.

This newly announced program comprises a series of compounds...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2004-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry